USING THE BIRMINGHAM VASCULITIS ACTIVITY SCORE (VERSION 3) FOR DIAGNOSING VASCULITIS

USING THE BIRMINGHAM VASCULITIS ACTIVITY SCORE (VERSION 3) FOR DIAGNOSING VASCULITIS

Bibliográfalaš dieđut
Váldodahkkit:	Mukhtyar, C, Brown, D, Hall, C, McLaren, J, Luqmani, R
Materiálatiipa:	Conference item
Almmustuhtton:	2009

Geahča maid

Using the Birmingham Vasculitis Activity Score (BVAS) for diagnosing vasculitis
Dahkki: Luqmani, R, et al.
Almmustuhtton: (2009)

Using the Birmingham vasculitis activity score (BVAS) to screen for vasculitis
Dahkki: Mukhtyar, C, et al.
Almmustuhtton: (2008)

Validation of the Birmingham Vasculitis Activity Score (Version 3)
Dahkki: Mukhtyar, C, et al.
Almmustuhtton: (2009)

Modification and validation of the Birmingham Vasculitis Activity Score (version 3).
Dahkki: Mukhtyar, C, et al.
Almmustuhtton: (2009)

A cross-sectional study of the Birmingham Vasculitis Activity Score version 3 in systemic vasculitis.
Dahkki: Suppiah, R, et al.
Almmustuhtton: (2011)

THE PROGNOSTIC VALUE OF THE BIRMINGHAM VASCULITIS ACTIVITY SCORE AND THE VASCULITIS DAMAGE INDEX IN ANCA-ASSOCIATED VASCULITIS
Dahkki: Suppiah, R, et al.
Almmustuhtton: (2011)

Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis.
Dahkki: Luqmani, R, et al.
Almmustuhtton: (1994)

Validation of a new version of the Birmingbam vasculitis activity score
Dahkki: Mukhtyar, C, et al.
Almmustuhtton: (2008)

Using the Birmingham Vasculitis Activity Score as a Screening Tool in Patients with Suspected Vasculitis
Dahkki: Floris, A, et al.
Almmustuhtton: (2016)

OP0055 Using the Birmingham Vasculitis Activity Score as a screening tool in patients with suspected vasculitis
Dahkki: Floris, A, et al.
Almmustuhtton: (2016)

Birmingham Vasculitis Activity Score (BVAS) for use in European multi-centre clinical trials
Dahkki: Luqmani, R, et al.
Almmustuhtton: (2001)

Validation of the Birmingham Vasculitis Activity Score (BVAS) for use in European multi-centre clinical trials.
Dahkki: Luqmani, R, et al.
Almmustuhtton: (2000)

Modified Birmingham vasculitis activity score for Wegener's granulomatosis (BVAS/WG) - Construct validity.
Dahkki: Maiden, N, et al.
Almmustuhtton: (2000)

Eular recommendations for vasculitis
Dahkki: Luqmani, R, et al.
Almmustuhtton: (2007)

DEVELOPMENT OF DIAGNOSTIC CRITERIA FOR PRIMARY ANCA-ASSOCIATED SYSTEMIC VASCULITIS (AASV)
Dahkki: McLaren, J, et al.
Almmustuhtton: (2003)

Diagnosis and assessment of systemic vasculitis.
Dahkki: McLaren, J, et al.
Almmustuhtton: (2002)

Performance of Birmingham Vasculitis Activity Score and disease extent index in childhood vasculitides.
Dahkki: Demirkaya, E, et al.
Almmustuhtton: (2012)

Cardiovascular involvement in primary systemic vasculitis.
Dahkki: Mukhtyar, C, et al.
Almmustuhtton: (2009)

DIAGNOSTIC CRITERIA FOR ANCA-ASSOCIATED PRIMARY SYSTEMIC VASCULITIS (AASV) IN PATIENTS PRESENTING WITH ACUTE PULMONARY AND/OR RENAL DISEASE
Dahkki: McLaren, J, et al.
Almmustuhtton: (2004)

Disease-specific quality indicators, guidelines, and outcome measures in vasculitis.
Dahkki: Mukhtyar, C, et al.
Almmustuhtton: (2007)

Cardiovascular outcomes in ANCA associated vasculitis
Dahkki: Mukhtyar, C, et al.
Almmustuhtton: (2008)

Outpatient assessment of systemic vasculitis.
Dahkki: Nataraja, A, et al.
Almmustuhtton: (2007)

Clinical Characteristics, Predictors for Mortality and Comparison of the Birmingham Vasculitis Activity Score and the Five-Factor Score on Survival in ANCA-Associated Vasculitis in Hong Kong
Dahkki: Joshua Ka Ho Yeung, et al.
Almmustuhtton: (2024-07-01)

The role of biologic therapies in the management of systemic vasculitis.
Dahkki: Chan, A, et al.
Almmustuhtton: (2006)

Cardiovascular outcomes in antineutrophil cytoplasm antibody associated vasculitis (AAV)
Dahkki: Mukhtyar, C, et al.
Almmustuhtton: (2008)

Remission in antineutrophil cytoplasmic antibody-associated systemic vasculitis.
Dahkki: Mukhtyar, C, et al.
Almmustuhtton: (2006)

Cardiovascular disease incidence and risk factors in ANCA-associated primary systemic vasculitis (AASV)
Dahkki: Salisbury, E, et al.
Almmustuhtton: (2003)

How to diagnose and treat secondary forms of vasculitis.
Dahkki: Luqmani, R, et al.
Almmustuhtton: (2005)

Current evidence of factors influencing remission, relapse, renal failure and mortality in patients with systemic vasculitis. A systematic review for the EULAR systemic vasculitis task force
Dahkki: Mukhtyar, C, et al.
Almmustuhtton: (2007)

Health-related quality of life in patients with newly diagnosed antineutrophil cytoplasmic antibody-associated vasculitis.
Dahkki: Walsh, M, et al.
Almmustuhtton: (2011)

INCIDENCE OF NON-FATAL CLINICAL CORONARY EVENTS IN PRIMARY ANCA-ASSOCIATED SYSTEMIC VASCULITIS (AASV)
Dahkki: Salisbury, E, et al.
Almmustuhtton: (2003)

CARDIOVASCULAR AND CEREBROVASCULAR DISEASE INCIDENCE AND RISK FACTORS IN ANCA-ASSOCIATED PRIMARY SYSTEMIC VASCULITIS (AASV)
Dahkki: Salisbury, E, et al.
Almmustuhtton: (2004)

A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS).
Dahkki: Stone, J, et al.
Almmustuhtton: (2001)

Vasculitis: an update.
Dahkki: Luqmani, R
Almmustuhtton: (2014)

Vasculitis: an update.
Dahkki: Luqmani, R
Almmustuhtton: (2014)

Disease activity assessment in childhood vasculitis: Development and preliminary validation of the Paediatric Vasculitis Activity Score (PVAS)
Dahkki: Dolezalova, P, et al.
Almmustuhtton: (2013)

Disease activity assessment in childhood vasculitis: development and preliminary validation of the Paediatric Vasculitis Activity Score (PVAS).
Dahkki: Dolezalova, P, et al.
Almmustuhtton: (2013)

Incidence of non-fatal clinical coronary events in primary ANCA-associated systemic vasculitis (aasv)
Dahkki: Salisbury, E, et al.
Almmustuhtton: (2003)

Calprotectin in systemic vasculitis
Dahkki: Pathare, S, et al.
Almmustuhtton: (2006)

Pharmacotherapy of vasculitis.
Dahkki: Chan, M, et al.
Almmustuhtton: (2009)